Cancer pathogenesis and therapy最新文献_第3页

Factors affecting the place of death in patients with liver cancer in China, 2013–2020: A population-based study 2013-2020年影响中国肝癌患者死亡地点的因素：基于人口的研究

Cancer pathogenesis and therapy Pub Date : 2024-04-01 DOI: 10.1016/j.cpt.2024.04.001

Xiaosheng Ding, Weiwei Shi, Jinlei Qi, Juan An, Weiran Xu, Hui Shi, Xixi Zheng, Xiaoyan Li

引用次数: 0

Cancer phylogenetic inference using copy number alterations detected from DNA sequencing data 利用 DNA 测序数据检测到的拷贝数改变进行癌症系统发育推断

Cancer pathogenesis and therapy Pub Date : 2024-04-01 DOI: 10.1016/j.cpt.2024.04.003

B. Lu

引用次数: 0

Association between autoimmunity-related disorders and prostate cancer: A Mendelian randomization study 自身免疫相关疾病与前列腺癌之间的关系：孟德尔随机研究

Cancer pathogenesis and therapy Pub Date : 2024-03-29 DOI: 10.1016/j.cpt.2024.03.002

{"title":"Association between autoimmunity-related disorders and prostate cancer: A Mendelian randomization study","authors":"","doi":"10.1016/j.cpt.2024.03.002","DOIUrl":"10.1016/j.cpt.2024.03.002","url":null,"abstract":"<div><h3>Background</h3><div>Although many epidemiological studies and meta-analyses have reported an association between autoimmune disorders and prostate cancer, none has reported a clear correlation or the direction of the association. The purpose of our study was to explore the potential relationship between autoimmunity-related disorders and prostate cancer using Mendelian randomization (MR).</div></div><div><h3>Methods</h3><div>We retrieved literature from PubMed using the keywords “autoimmune disorder” AND “prostate cancer” to find more clues on the correlation between prostate cancer and autoimmunity-related disorder. Based on this literature search, we selected 16 autoimmunity-related disorders that had genome-wide association study (GWAS) data and may be associated with prostate cancer. The inverse variance weighting (IVW) method was applied as our primary analysis for two-sample MR and multivariate MR analysis to estimate the odds ratio (OR) and 95% confidence interval (CI). We further verified the robustness of our conclusions using a series of sensitivity analyses.</div></div><div><h3>Results</h3><div>The autoimmunity-related diseases selected include rheumatoid arthritis, ankylosing spondylitis, coxarthrosis, gonarthrosis, Crohn's disease, ulcerative colitis, irritable bowel syndrome, celiac disease, primary sclerosing cholangitis, asthma, type 1 diabetes, systemic lupus erythematosus, multiple sclerosis, autoimmune hyperthyroidism, psoriatic arthropathies, and polymyalgia rheumatica. The results of inverse variance weighting (IVW suggested that six diseases were associated with the development of prostate cancer. The three diseases that may increase the risk of prostate cancer are rheumatoid arthritis (<em>P</em> = 0.001), coxarthrosis (<em>P</em> < 0.001), and gonarthrosis (<em>P</em> = 0.008). The three possible protective factors against prostate cancer are primary sclerosing cholangitis (<em>P</em> = 0.001), autoimmune hyperthyroidism (<em>P</em> = 0.011), and psoriatic arthropathies (<em>P</em> = 0.001). Horizontal pleiotropy was not observed in the MR-Egger test.</div></div><div><h3>Conclusions</h3><div>Our findings provide predictive genetic evidence for an association between autoimmune disorders and prostate cancer. Further research is needed to explore the underlying mechanisms of comorbidities at the molecular level.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 4","pages":"Pages 292-298"},"PeriodicalIF":0.0,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000211/pdfft?md5=aadc6f8c5ef4020d01d627f2bf5d8edb&pid=1-s2.0-S2949713224000211-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140402676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cover 封面

Cancer pathogenesis and therapy Pub Date : 2024-03-26 DOI: 10.1016/S2949-7132(24)00006-5

引用次数: 0

Long-term adoptive immunotherapy achieves complete response and bone lesion repair in an elderly patient with macrofocal multiple myeloma 长期采用免疫疗法使一名老年大灶多发性骨髓瘤患者获得完全应答并修复骨病变

Cancer pathogenesis and therapy Pub Date : 2024-03-16 DOI: 10.1016/j.cpt.2024.03.001

引用次数: 0

Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial 安罗替尼加培罗单抗作为小细胞肺癌二线治疗的有效性和安全性：多中心、开放标签、单臂II期试验

Cancer pathogenesis and therapy Pub Date : 2024-02-07 DOI: 10.1016/j.cpt.2024.02.001

{"title":"Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial","authors":"","doi":"10.1016/j.cpt.2024.02.001","DOIUrl":"10.1016/j.cpt.2024.02.001","url":null,"abstract":"<div><h3>Background</h3><div>Currently, the need for new therapeutic strategies involving programmed cell death protein-1 (PD-1) monoclonal antibodies in the second-line setting of small cell lung cancer (SCLC) is urgent. This study aimed to evaluate the efficacy and safety of anlotinib plus penpulimab as a second-line treatment for patients with SCLC who progressed after first-line platinum-based chemotherapy.</div></div><div><h3>Methods</h3><div>This study included the patients from Cohort 4 of a single-arm, open-label, multicenter, phase II clinical trial. A safety run-in phase was performed under anlotinib (10/12 mg <em>quaque die</em> [QD], days 1–14) plus penpulimab (200 mg intravenously [IV], day 1) in a 21-day cycle, followed by the formal trial in which the patients received anlotinib (12 mg QD, days 1–14) plus penpulimab (200 mg IV, day 1) in a 21-day cycle. The primary endpoint of the safety run-in phase was safety. The primary endpoint of the formal trial phase was the objective response rate (ORR).</div></div><div><h3>Results</h3><div>From April 28, 2020, to November 24, 2020, 21 patients were enrolled from 11 hospitals, including 2 in the safety run-in phase and 19 in the formal trial phase. In the formal trial phase, the ORR was 42.1% (8/19; 95% confidence interval [CI]: 17.7–66.6%). The median progression-free survival was 4.8 months (95% CI: 2.9–11.3 months), and the median overall survival was 13.0 months (95% CI: 4.6–not applicable [NA] months). The incidence of ≥grade 3 treatment-related adverse events (TRAEs) was 52.4% (11/21), and the incidence of treatment-related serious adverse events (AEs) was 28.6% (6/21). Two AE-related deaths occurred. The most common AEs were hypertension (57.1%, 12/21), hypothyroidism (42.9%, 9/21), and hypertriglyceridemia (38.1%, 8/21).</div></div><div><h3>Conclusions</h3><div>In patients with SCLC who progressed after first-line platinum-based chemotherapy, the second-line anlotinib plus penpulimab treatment demonstrates promising anti-cancer activity and a manageable safety profile, which warrants further investigation.</div></div><div><h3>Trial registration</h3><div>No. <span><span>NCT04203719</span><svg><path></path></svg></span>, <span><span>https://clinicaltrials.gov/</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 4","pages":"Pages 268-275"},"PeriodicalIF":0.0,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000041/pdfft?md5=00ec1c474c71cd0b292b4f28a4c4d00e&pid=1-s2.0-S2949713224000041-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139883467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Self-healing hydrogels for enhancing chemotherapy drug efficacy: Advancements in anti-sarcoma and carcinoma therapies and clinical trial feasibility 用于提高化疗药物疗效的自愈合水凝胶：抗肉瘤和癌症疗法的进展与临床试验的可行性

Cancer pathogenesis and therapy Pub Date : 2024-02-02 DOI: 10.1016/j.cpt.2024.01.003

Luc Taylor

引用次数: 0

Autophagy as a targeted therapeutic approach for skin cancer: Evaluating natural and synthetic molecular interventions 自噬作为皮肤癌的靶向治疗方法：评估天然和合成分子干预措施

Cancer pathogenesis and therapy Pub Date : 2024-02-01 DOI: 10.1016/j.cpt.2024.01.002

Md. Liakot Ali , Amdad Hossain Roky , S.M. Asadul Karim Azad , Abdul Halim Shaikat , Jannatul Naima Meem , Emtiajul Hoque , Abu Mohammed Fuad Ahasan , Mohammed Murshedul Islam , Md. Saifur Rahaman Arif , Md. Saqline Mostaq , Md. Zihad Mahmud , Mohammad Nurul Amin , Md. Ashiq Mahmud

{"title":"Autophagy as a targeted therapeutic approach for skin cancer: Evaluating natural and synthetic molecular interventions","authors":"Md. Liakot Ali , Amdad Hossain Roky , S.M. Asadul Karim Azad , Abdul Halim Shaikat , Jannatul Naima Meem , Emtiajul Hoque , Abu Mohammed Fuad Ahasan , Mohammed Murshedul Islam , Md. Saifur Rahaman Arif , Md. Saqline Mostaq , Md. Zihad Mahmud , Mohammad Nurul Amin , Md. Ashiq Mahmud","doi":"10.1016/j.cpt.2024.01.002","DOIUrl":"10.1016/j.cpt.2024.01.002","url":null,"abstract":"<div><div>Skin cancer, a prevalent malignancy worldwide, poses significant health concerns owing to its increasing incidence. Autophagy, a natural cellular process, is a pivotal event in skin cancer and has advantageous and detrimental effects. This duality has prompted extensive investigations into medical interventions targeting autophagy modulation for their substantial therapeutic potential. This systematic review aimed to investigate the relationship between skin cancer and autophagy and the contribution and mechanism of autophagy modulators in skin cancer. We outlined the effectiveness and safety of targeting autophagy as a promising therapeutic strategy for the treatment of skin cancer. This comprehensive review identified a diverse array of autophagy modulators with promising potential for the treatment of skin cancer. Each of these compounds demonstrates efficacy through distinct physiological mechanisms that have been elucidated in detail. Interestingly, findings from a literature search indicated that none of the natural, synthetic, or semisynthetic compounds exhibited notable adverse effects in either human or animal models. Consequently, this review offers novel mechanistic and therapeutic perspectives on the targeted modulation of autophagy in skin cancer.</div></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 4","pages":"Pages 231-245"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713224000028/pdfft?md5=49e34dccae0c252025870fda72f8c316&pid=1-s2.0-S2949713224000028-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial 伊奈他单抗联合吡罗替尼和口服长春瑞滨治疗人类表皮生长因子受体 2 阳性晚期乳腺癌患者：单臂 2 期临床试验

Cancer pathogenesis and therapy Pub Date : 2024-01-01 DOI: 10.1016/j.cpt.2023.10.004

Nan Jin , Yi Xu , Siqi Wang , Chunxiao Sun , Xueqi Yan , Fan Yang , Yan Liang , Weiwei Chen , Xiang Huang

{"title":"Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial","authors":"Nan Jin , Yi Xu , Siqi Wang , Chunxiao Sun , Xueqi Yan , Fan Yang , Yan Liang , Weiwei Chen , Xiang Huang","doi":"10.1016/j.cpt.2023.10.004","DOIUrl":"10.1016/j.cpt.2023.10.004","url":null,"abstract":"<div><h3>Background</h3><p>Human epidermal growth factor receptor 2 (HER2)-targeted agents have significantly improved the outcomes of patients with HER2-positive breast cancer; however, a large proportion of patients still develop resistance to trastuzumab. In this study, we investigated the efficacy and safety of inetetamab, another anti-HER2 antibody, combined with pyrotinib and oral vinorelbine in patients with HER2-positive advanced breast cancer so as to provide new ideas for the treatment.</p></div><div><h3>Methods</h3><p>In this prospective, single-arm, phase 2 trial, patients with HER2-positive advanced breast cancer with disease progression after trastuzumab were recruited. Patients received a combination of inetetamab (loading dose of 8 mg/kg and subsequent doses of 6 mg/kg intravenously once every 3 weeks), pyrotinib (400 mg orally once daily), and vinorelbine (60 mg/m<sup>2</sup> orally once weekly) until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), overall survival (OS), disease control rate (DCR), and safety.</p></div><div><h3>Results</h3><p>Between February 13, 2022 and December 25, 2022, 30 patients were screened and enrolled in this study. The median age of the patients at enrollment was 54 years, 12 patients (40.0 %) had hormone-receptor-positive disease and 23 patients (76.7 %) had visceral metastasis. The median PFS was 8.63 months (95 % confidence interval [CI] 4.15–13.12 months). The median OS was not reached. The ORR was 53.3 % (16/30) and the DCR was 96.7 % (29/30). The most common Grade III/IV adverse events were leukopenia (<em>n</em> = 5, 16.7 %), neutropenia (<em>n</em> = 4, 13.3 %), and diarrhea (<em>n</em> = 3, 10 %). No treatment-related serious adverse events or deaths occurred.</p></div><div><h3>Conclusions</h3><p>The combination regimen of inetetamab, pyrotinib, and oral vinorelbine showed encouraging efficacy and favorable safety in patients with HER2-positive advanced breast cancer and could be considered as an alternative treatment option for the patients.</p></div><div><h3>Trial registration</h3><p>No.NCT05823623; <span>https://www.clinicaltrials.gov/</span><svg><path></path></svg>.</p></div>","PeriodicalId":93920,"journal":{"name":"Cancer pathogenesis and therapy","volume":"2 1","pages":"Pages 31-37"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949713223000861/pdfft?md5=dc961df2356f92d5808448e7ca98f6ad&pid=1-s2.0-S2949713223000861-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136128019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cover 封面

Cancer pathogenesis and therapy Pub Date : 2024-01-01 DOI: 10.1016/S2949-7132(23)00099-X

引用次数: 0